Evidence map›Paper›PMID 31841454›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Long Noncoding RNA (lncRNA) FOXD2-AS1 Promotes Cell Proliferation and Metastasis in Hepatocellular Carcinoma by Regulating MiR-185/AKT Axis.

Zheng Chen, Zhen Zhang, Dongbo Zhao, Wei Feng, Fanlai Meng, Shihui Han, Bin Lin, Xin Shi

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zheng ChenDepartment of General Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu, China (mainland).
Zhen ZhangDepartment of Anesthesiology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu, China (mainland).
Dongbo ZhaoDepartment of General Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu, China (mainland).
Wei FengDepartment of General Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu, China (mainland).
Fanlai MengDepartment of Pathology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu, China (mainland).
Shihui HanDepartment of General Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu, China (mainland).
Bin LinDepartment of General Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu, China (mainland).
Xin ShiDepartment of General Surgery, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian People's Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu, China (mainland).
Nanjing Drum Tower Hospital · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The aim of this study was to investigate the effects and mechanisms of long noncoding (lnc) RNA FOXD2-AS1 in hepatocellular carcinoma development. MATERIAL AND METHODS Collecting the 3 pairs of adjacent and hepatocellular carcinoma tissue and analysis by gene chip. Evaluating the FOXD2-AS1 expression by in situ hybridization assay. Evaluating the FOXD2-AS1 to Bel-7402 biological activity in vitro study by Cell Counting Kit-8, flow cytometry, Transwell and wound healing assay and correlation between miR-185 by dual-luciferase reporter assay. The relative proteins expressions were evaluated by western blot assay. RESULTS FOXD2-AS1 was significantly upregulation in hepatocellular carcinoma tissues. FOXD2-AS1 knockdown suppressed Bel-7401 cell biological activities (proliferation, invasion, and migration) with miR-185 overexpression and AKT depressing in cell expression. CONCLUSIONS LncRNA FOXD2-AS1 promoted hepatocellular carcinoma development by regulation miR-185/AKT axis.

Indexed as

Signal TransductionApoptosisBase SequenceCarcinoma, HepatocellularCell Line, TumorCell MovementCell NucleusCell ProliferationFemaleGene Expression Regulation, NeoplasticHepatocytesHumansLiver NeoplasmsMaleMicroRNAsMiddle Agedlong non-coding RNA FOXD2-AS1, humanMicroRNAsMIRN185 microRNA, humanProto-Oncogene Proteins c-aktRNA, Long NoncodingRNA, Messenger

Identifiers

PMID31841454
PMCPMC6929557
OpenAlexW2996594296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.